$ONC
BeiGene, Ltd. Stock $onc

$onc Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000165130823000036 Filed on February 27, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$447.8M	$2.698B	$1.416B
YoY Change	46.04%	98.0%	20.37%
Cost Of Revenue	$81.79M	$501.9M	$286.5M
YoY Change	25.37%	52.43%	73.72%
Gross Profit	$366.0M	$2.196B	$1.129B
YoY Change	51.63%	112.52%	11.67%
Gross Profit Margin	81.74%	81.39%	79.77%
Selling, General & Admin	$328.5M	$2.367B	$1.278B
YoY Change	11.52%	7.91%	29.06%
% of Gross Profit	89.75%	107.81%	113.14%
Research & Development	$408.6M	$3.135B	$1.641B
YoY Change	4.79%	10.96%	12.42%
% of Gross Profit	111.63%	142.76%	145.25%
Depreciation & Amortization	$20.01M		$66.28M
YoY Change	20.55%		42.67%
% of Gross Profit	5.47%		5.87%
Operating Expenses	$737.1M	$5.519B	$2.918B
YoY Change	7.68%	6.59%	19.15%
Operating Profit	-$371.3M	-$3.323B	-$1.790B
YoY Change	-16.25%	-19.82%	24.39%
Interest Expense	$102.6M	$246.5M	-$1.399B
YoY Change	373.18%	-307.01%	1172.74%
% of Operating Profit
Other Income/Expense, Net	$18.30M	-$1.219M	-$223.9M
YoY Change	52.95%	-524.74%	-1507.52%
Pretax Income	-$336.9M	-$3.078B	-$1.961B
YoY Change	-20.01%	-27.82%	36.32%
Income Tax	$11.49M	$130.8M	$42.78M
% Of Pretax Income
Net Earnings	-$348.4M	-$3.208B	-$2.004B
YoY Change	-19.77%	-24.46%	41.78%
Net Earnings / Revenue	-77.81%	-118.93%	-141.52%
Basic Earnings Per Share	-$0.26		-$1.49
Diluted Earnings Per Share	-$0.26	-$2.38	-$1.49
COMMON SHARES
Basic Shares Outstanding	1.356B shares	1.350B shares	1.341B shares
Diluted Shares Outstanding	1.354B shares		1.341B shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.32B	$26.79B	$31.45B
YoY Change	289.43%	304.86%	-25.5%
Cash & Equivalents	$3.539B	$3.870B
Short-Term Investments	$6.499B	$6.659B	$11.34B
Other Short-Term Assets	$3.875B	$6.136B	$1.339B
YoY Change	-72.35%	22575.15%	6.94%
Inventory	$297.0M	$282.3M	$1.954B
Prepaid Expenses
Receivables	$309.6M	$173.2M	$1.202B
Other Receivables	$62.13M	$89.94M	$231.4M
Total Short-Term Assets	$4.704B	$5.207B	$36.17B
YoY Change	-32.29%	-31.61%	-25.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$925.4M	$845.9M	$6.117B
YoY Change	48.14%	43.97%	51.21%
Goodwill	$109.0K	$109.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$32.37M	$27.71M	$637.8M
YoY Change	44.26%	20.71%	-0.74%
Other Assets	$173.4M	$170.4M	$528.9M
YoY Change	5.36%	4.52%	-53.54%
Total Long-Term Assets	$1.252B	$1.172B	$8.050B
YoY Change	16.7%	13.58%	21.17%
TOTAL ASSETS
Total Short-Term Assets	$4.704B	$5.207B	$36.17B
Total Long-Term Assets	$1.252B	$1.172B	$8.050B
Total Assets	$5.957B	$6.379B	$44.22B
YoY Change	-25.74%	-26.22%	-19.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$241.4M	$294.8M	$2.482B
YoY Change	1.88%	12.34%	-4.08%
Accrued Expenses	$417.9M	$467.4M	$1.683B
YoY Change	8.28%	-16.25%	42.59%
Deferred Revenue	$185.5M	$213.9M
YoY Change	13.33%	14.11%
Short-Term Debt	$1.834B	$2.203B	$2.203B
YoY Change	-25.84%	-15.99%	-15.99%
Long-Term Debt Due	1.935B cnies	2.269B cnies	$263.9M
YoY Change	-25.06%	-16.73%	67.25%
Total Short-Term Liabilities	$1.255B	$1.469B	$10.30B
YoY Change	-8.85%	-8.19%	0.97%
LONG-TERM LIABILITIES
Long-Term Debt	1.417B cnies	1.443B cnies	$1.683B
YoY Change	10.86%	12.0%	7.61%
Other Long-Term Liabilities	$45.62M	$46.10M	$1.861B
YoY Change	-11.98%	-15.01%	-46.34%
Total Long-Term Liabilities	$544.9M	$527.4M	$3.544B
YoY Change	-28.26%	-34.35%	-29.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.255B	$1.469B	$10.30B
Total Long-Term Liabilities	$544.9M	$527.4M	$3.544B
Total Liabilities	$1.799B	$1.996B	$13.89B
YoY Change	-15.75%	-16.94%	-8.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.429B	-$7.080B
YoY Change	37.56%	42.57%
Common Stock	$136.0K	$135.0K
YoY Change	2.26%	1.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.157B	$4.383B	$30.33B
YoY Change
Total Liabilities & Shareholders Equity	$5.957B	$6.379B	$44.22B
YoY Change	-25.74%	-26.22%	-19.86%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$348.4M	-$3.208B	-$2.004B
YoY Change	-19.77%	-24.46%	41.78%
Depreciation, Depletion And Amortization	$20.01M		$66.28M
YoY Change	20.55%		42.67%
Cash From Operating Activities	-$563.8M	-$1.341B	-$1.497B
YoY Change	138.32%	-56.88%	15.24%
INVESTING ACTIVITIES
Capital Expenditures	$125.6M	$861.3M	$325.4M
YoY Change	178.27%	-169.45%	23.77%
Acquisitions
YoY Change
Other Investing Activities	$9.250M	-$3.814B	$0.00
YoY Change	-99.55%	-1747.16%
Cash From Investing Activities	$241.1M	-$4.675B	$1.077B
YoY Change	14.58%	363.55%	68.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net	$1.457M		$0.00
YoY Change
Cash From Financing Activities	-$19.87M	-891.3M	-$18.97M
YoY Change	76.34%	-104.15%	-100.52%
NET CHANGE
Cash From Operating Activities	-$563.8M	-1.341B	-$1.497B
Cash From Investing Activities	$241.1M	-4.675B	$1.077B
Cash From Financing Activities	-$19.87M	-891.3M	-$18.97M
Net Change In Cash	-$331.3M	-6.908B	-$507.9M
YoY Change	1064.93%	-139.83%	-116.97%
FREE CASH FLOW
Cash From Operating Activities	-$563.8M	-$1.341B	-$1.497B
Capital Expenditures	$125.6M	$861.3M	$325.4M
Free Cash Flow	-$689.4M	-$2.202B	-$1.822B
YoY Change	144.72%	17.82%	16.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001651308
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37686
CY2022	dei	Entity Registrant Name EntityRegistrantName	BEIGENE, LTD.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1209416
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	c/o Mourant Governance Services (Cayman) Limited
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	94 Solaris Avenue, Camana Bay
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Grand Cayman
CY2022	dei	Entity Address Country EntityAddressCountry	KY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	KY1-1108
CY2022	dei	City Area Code CityAreaCode	345
CY2022	dei	Local Phone Number LocalPhoneNumber	949 4123
CY2022	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	BGNE
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	16800000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1356140180	shares
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1356140180	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3869564000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4375678000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	196000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	328000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	665251000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	2241962000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	173168000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	483113000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	282346000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	242626000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216553000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	270173000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5207078000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	7613880000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5277000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6881000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	845946000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	587605000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109960000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117431000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40616000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46679000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170413000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	163049000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1172212000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	921645000	usd
CY2022Q4	us-gaap	Assets Assets	6379290000	usd
CY2021Q4	us-gaap	Assets Assets	8535525000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	294781000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	262400000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	467352000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	558055000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	213861000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	187414000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	25189000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	21395000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24041000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21925000	usd
CY2022Q4	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	114335000	usd
CY2021Q4	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	120801000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	328969000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	427565000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1468528000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1599555000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	209148000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	202113000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42026000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	220289000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34517000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43041000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15996000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	14169000	usd
CY2022Q4	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	179625000	usd
CY2021Q4	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	269561000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46095000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	54234000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	527407000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	803407000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1995935000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2402962000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1356140180	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1356140180	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1334804281	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1334804281	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	135000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	133000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11540979000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11191007000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-77417000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17950000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7080342000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5076527000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4383355000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6132563000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6379290000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8535525000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1415921000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1176283000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	308874000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	286475000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	164906000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	70657000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1640508000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1459239000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-223852000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1294877000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1277852000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	990123000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	600176000	usd
CY2022	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	751000	usd
CY2021	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	750000	usd
CY2020	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	846000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	3205586000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	2615018000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1966556000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1789665000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1438735000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-1657682000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	52480000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-15757000	usd
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1998000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15904000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37490000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1961037000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1438588000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1618194000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42778000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19228000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10397000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2003815000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3617000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2003815000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1457816000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1624974000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.50
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.50
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1340729572	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340729572	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1206210049	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1206210049	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1085131783	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1085131783	shares
CY2022	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-19.43
CY2022	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-19.43
CY2021	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-15.71
CY2021	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-15.71
CY2020	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-19.47
CY2020	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-19.47
CY2022	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	103133044	shares
CY2022	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	103133044	shares
CY2021	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	92785388	shares
CY2021	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	92785388	shares
CY2020	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	83471676	shares
CY2020	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	83471676	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-2003815000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-90421000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	13714000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	23603000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-365000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-1865000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	8113000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5311000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4571000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-419000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2099182000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1446808000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1613520000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3489000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2099182000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1446808000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1610031000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2003815000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66278000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	46457000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31789000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	303162000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	240712000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	183481000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	68665000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	83500000	usd
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	109500000	usd
CY2022	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-96402000	usd
CY2021	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-112486000	usd
CY2020	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-113986000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-21996000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	7632000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	11826000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2059000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3377000	usd
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	261000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	9047000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	23510000	usd
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-4673000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-304112000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	423019000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10363000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56689000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	153333000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	58906000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3282000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	107128000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	56217000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4352000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	20008000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	95835000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	45627000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	140044000	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	185012000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-151816000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	407703000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1209000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2620000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-25503000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1496619000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1298723000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1283461000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	325434000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	262942000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	117508000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1485000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2147881000	usd
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5663727000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1563618000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3146891000	usd
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2751075000	usd
CY2022	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	143665000	usd
CY2021	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	8500000	usd
CY2020	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	109500000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	43409000	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	15911000	usd
CY2021	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	43500000	usd
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	26681000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	2025000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1077123000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	640659000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3168366000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	3392616000	usd
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4232017000	usd
CY2022	bgne	Proceeds From Research And Development Financing Liability ProceedsFromResearchAndDevelopmentFinancingLiability	0	usd
CY2021	bgne	Proceeds From Research And Development Financing Liability ProceedsFromResearchAndDevelopmentFinancingLiability	0	usd
CY2020	bgne	Proceeds From Research And Development Financing Liability ProceedsFromResearchAndDevelopmentFinancingLiability	616834000	usd
CY2022	bgne	Payments To Acquire Interest In Joint Venture Financing Activities PaymentsToAcquireInterestInJointVentureFinancingActivities	0	usd
CY2021	bgne	Payments To Acquire Interest In Joint Venture Financing Activities PaymentsToAcquireInterestInJointVentureFinancingActivities	0	usd
CY2020	bgne	Payments To Acquire Interest In Joint Venture Financing Activities PaymentsToAcquireInterestInJointVentureFinancingActivities	28723000	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	37372000	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	16838000	usd
CY2020	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	110208000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	132061000	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	313774000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	406449000	usd
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	323697000	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	417081000	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	321754000	usd
CY2020	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	12247000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	46964000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	92762000	usd
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	93101000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18971000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3636911000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5202826000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-69383000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14035000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18231000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-507850000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2992882000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	769230000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4382887000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1390005000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	620775000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3875037000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4382887000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1390005000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3869564000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4375678000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1381950000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	196000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	328000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	307000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5277000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6881000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	7748000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	29500000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	15695000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10596000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	25169000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	29967000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	44130000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	95346000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	53197000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	42762000	usd
CY2022	bgne	Acquired In Process Research And Development But Not Yet Paid AcquiredInProcessResearchAndDevelopmentButNotYetPaid	0	usd
CY2021	bgne	Acquired In Process Research And Development But Not Yet Paid AcquiredInProcessResearchAndDevelopmentButNotYetPaid	75000000	usd
CY2020	bgne	Acquired In Process Research And Development But Not Yet Paid AcquiredInProcessResearchAndDevelopmentButNotYetPaid	0	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	940461000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2069610000	usd
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	93101000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	183481000	usd
CY2020	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3545000	usd
CY2020	bgne	Acquisition Of Joint Venture Minority Interest AcquisitionOfJointVentureMinorityInterest	28715000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	15071000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3803281000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	92762000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	240712000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	11008000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6132563000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	152000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	46964000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	303162000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-95367000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2003815000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4383355000	usd
CY2022Q4	bgne	Number Of Persons NumberOfPersons	2700	people
CY2022Q4	bgne	Product Candidate ProductCandidate	3	product
CY2022Q4	dei	Entity Number Of Employees EntityNumberOfEmployees	9000	employee
CY2022Q4	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	29	country
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the </span></div>standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist of cash and cash equivalents, short-term investments, and accounts receivable.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, $3,869,564 and $4,375,678 were deposited with various major reputable financial institutions located in the PRC and international financial institutions outside of the PRC, respectively. The deposits placed with </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. As of December 31, 2022 and 2021, the Company had short-term investments amounting to $665,251 and $2,241,962, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, the Company’s short-term investments were comprised of U.S. treasury securities. The Company believes that U.S. treasury securities are of high credit quality and continually monitors the credit worthiness of these institutions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the Company had accounts receivable, net of $173,168 and $483,113, respectively. Accounts receivable, net represent amounts arising from product sales and amounts due from its collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer concentration risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, sales to the Company's four largest product distributors, Sinopharm, Shanghai Pharmaceutical, ASD Specialty Healthcare and China Resources represented approximately 18.1%, 15.5%, 14.2% and 12.1% of product revenue, respectively, and collectively, represented approximately 57.0% of trade accounts receivable as of December 31, 2022. For the year ended December 31, 2022, the Company's collaboration revenue consisted entirely of revenue recognized under its out-licensing collaboration agreements with Novartis. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, sales to the Company's three largest product distributors, Sinopharm, China Resources, and Shanghai Pharmaceutical represented approximately 26.0%, 19.9% and 16.7% of product revenue, respectively, and collectively, represented approximately 23.4% of trade accounts receivable as of December 31, 2021. For the year ended December 31, 2021, the Company's collaboration revenue consisted entirely of revenue recognized under its out-licensing collaboration agreements with Novartis. Receivables from Novartis represented approximately 66.4% of trade accounts receivable as of December 31, 2021, primarily due to the invoicing of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront fee related to the Ociperlimab option, collaboration and license agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, sales to the Company's two largest product distributors, China Resources and Sinopharm, represented approximately 38.7% and 25.4% of product revenue, respectively, and collectively, represented approximately 59.6% of trade accounts receivable as of December 31, 2020.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business, customer, political, social and economic risks</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in a dynamic biopharmaceutical industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: changes in the overall demand for services and products; competitive pressures due to existing competitors and new entrants; advances and new trends in new drugs and industry standards; changes in clinical research organizations, contract manufacturers and other key vendors; changes in certain strategic relationships or customer relationships; regulatory considerations; intellectual property considerations; and risks associated with the Company’s ability to attract and retain employees necessary to support its growth. The Company’s operations could be also adversely affected by significant political, economic and social uncertainties in the PRC and in relations between the PRC and United States.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Currency convertibility risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company’s expenses, assets and liabilities are denominated in RMB. In 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the People’s Bank of China (the PBOC). However, the unification of the exchange rates does not imply that the RMB may be readily convertible into U.S. dollar or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approvals of foreign currency payments by the PBOC or other institutions require submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the value of the RMB is subject to changes in central government policies and international economic and political developments affecting supply and demand in the PRC foreign exchange trading system market.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rate risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to foreign exchange risk arising from various currency exposures. The Company's reporting currency is the U.S. dollar, but a portion of its operating transactions and assets and liabilities are in other currencies, such as RMB, Euro, and Australian dollar. While the Company holds significant amounts of RMB, and is subject to foreign currency exchange risk upon revaluation or translation into the Company's reporting currency, the Company expects to utilize its existing RMB cash deposits in the operation of its China business over the next several years, and as a result, has not used derivative financial instruments to hedge exposure to such risk.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RMB is not freely convertible into foreign currencies for capital account transactions. The value of RMB against the U.S. dollar and other currencies is affected by, among other things, changes in China’s political and economic conditions and China’s foreign exchange prices. Since July 21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For RMB against U.S. dollar, there was depreciation of approximately 8.2%, appreciation of approximately 2.3% and appreciation of approximately 6.3%, in the years ended December 31, 2022, 2021 and 2020. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the Company needs to convert U.S. dollar into RMB for capital expenditures and working capital and other business purposes, appreciation of RMB against U.S. dollar would have an adverse effect on the RMB amount the Company would receive from the conversion. Conversely, if the Company decides to convert RMB into U.S. dollar for the purpose of making payments for dividends on ordinary shares, strategic acquisitions or investments or other business purposes, appreciation of U.S. dollar against RMB would have a negative effect on the U.S. dollar amount available to the Company.</span></div>In addition, a significant depreciation of the RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of the Company's foreign cash balances and trade receivables. Further, volatility in exchange rate fluctuations may have a significant impact on the foreign currency translation adjustments recorded in other comprehensive income (loss). The revaluation impact of foreign currencies held in U.S. functional currency subsidiaries may result in significant foreign exchange gains (losses) in the consolidated statement of operations. The Company has not used derivative financial instruments to hedge exposure to foreign exchange risk.
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3869564000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4375678000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	665251000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	2241962000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	173168000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	483113000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revision of prior period financial statements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluates the recoverability of its deferred tax assets on a jurisdiction-by-jurisdiction basis by assessing the adequacy of future expected taxable income from all sources, including reversal of temporary differences, forecasted operating earnings and available tax planning strategies in accordance with ASC 740. This assessment is subject to a high degree of subjectivity, as the sources of income rely heavily on estimates that are based on a number of factors, including historical experience and short-range and long-range business forecasts. A valuation allowance is provided when the Company determines that it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the third quarter of 2022, the Company determined that the majority of its net deferred tax assets (primarily in the U.S.) were realizable on a more-likely-than-not basis, primarily due to cumulative pre-tax income at the taxpaying entity and the weighting of available positive and negative evidence. Accordingly, no valuation allowance was previously recorded related to those deferred tax assets. In October 2022, in connection with the preparation of its condensed consolidated financial statements for the three and nine months ended September 30, 2022, the Company reassessed its position on the realizability of its net deferred tax assets and determined that the negative evidence associated with cumulative losses at the consolidated financial statement level are not able to be overcome by other positive evidence, and therefore, a valuation allowance should be applied to its net deferred tax asset balance. The Company determined the previous conclusion to not apply a valuation allowance to certain net deferred tax assets was an error. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with Staff Accounting Bulletin (SAB) No. 99, “Materiality,” and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company evaluated the error and determined that the related impact was not material to any of its previously issued financial statements, but that correcting the cumulative impact of the error would be significant to its statements of operations for the twelve months ended December 31, 2022. Accordingly, the Company has revised the annual periods of fiscal year 2021 and 2020 consolidated financial statements and related notes included herein to record a valuation allowance against the Company’s net deferred tax asset balance for all periods presented. A summary of revisions to previously reported financial statements is presented in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revision of Prior Period Financial Statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> have been updated to </span></div>reflect the revision. The Company will also correct previously reported financial information for this error in its future filings, as applicable.
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	921645000	usd
CY2021Q4	us-gaap	Assets Assets	8535525000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5076527000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	6132563000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8535525000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19228000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10397000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1457816000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1624974000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.50
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.50
CY2021	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-15.71
CY2021	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-15.71
CY2020	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-19.47
CY2020	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-19.47
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1446808000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1613520000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1446808000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1610031000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3377000	usd
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	261000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1298723000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1283461000	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	940461000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3803281000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6132563000	usd
CY2022Q1	bgne	Number Of Products Initiated Marketing And Promotion NumberOfProductsInitiatedMarketingAndPromotion	5	product
CY2022	bgne	Reimbursement Expense ReimbursementExpense	50183000	usd
CY2021	bgne	Reimbursement Expense ReimbursementExpense	42836000	usd
CY2020	bgne	Reimbursement Expense ReimbursementExpense	11620000	usd
CY2022	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	74165000	usd
CY2021	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	141894000	usd
CY2020	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	125300000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5473000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	7209000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	674262000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9011000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	665251000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	2245662000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3700000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	2241962000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	57054000	usd
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	43722000	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	5065000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	88957000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	78140000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	20886000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9397000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	172503000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	155089000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	282346000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	242626000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	25938000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	22536000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	18271000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6834000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4892000	usd
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	2465000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1299000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1823000	usd
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1018000	usd
CY2022	us-gaap	Lease Cost LeaseCost	34071000	usd
CY2021	us-gaap	Lease Cost LeaseCost	29251000	usd
CY2020	us-gaap	Lease Cost LeaseCost	21754000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109960000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117431000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24041000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21925000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34517000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43041000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	58558000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	64966000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	26278000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21647000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11312000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2821000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	966000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	63024000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4466000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	58558000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	28064000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	19962000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	17571000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22278000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	37454000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17634000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0576
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0515
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	723789000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	525048000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	171470000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	124286000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	293627000	usd
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	186843000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	845946000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	587605000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	293627000	usd
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	186843000	usd
CY2022	us-gaap	Depreciation Depreciation	62302000	usd
CY2021	us-gaap	Depreciation Depreciation	44742000	usd
CY2020	us-gaap	Depreciation Depreciation	30943000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49551000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8935000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40616000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	51710000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5031000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	46679000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3976000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1715000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	846000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3920000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3920000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3920000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3920000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3670000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	21266000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40616000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1961037000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1438588000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	10511000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1618194000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27905000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	15252000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16121000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4844000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-9000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-5678000	usd
CY2022	bgne	Current Other Income Tax Expense Benefit CurrentOtherIncomeTaxExpenseBenefit	6547000	usd
CY2021	bgne	Current Other Income Tax Expense Benefit CurrentOtherIncomeTaxExpenseBenefit	805000	usd
CY2020	bgne	Current Other Income Tax Expense Benefit CurrentOtherIncomeTaxExpenseBenefit	68000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	39296000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16048000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3480000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4919000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-114000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-35000	usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	2000	usd
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-1704000	usd
CY2020	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3482000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3180000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-114000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42778000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19228000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10397000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1961037000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1438588000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1618194000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-490259000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-359647000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-404549000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	288133000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	185874000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	218473000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	30598000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-2826000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	8436000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	82060000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	33872000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-27411000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-22032000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-3827000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	229550000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	254768000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	237153000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	49116000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	31530000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	23257000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42778000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19228000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10397000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.022
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	58835000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	798563000	usd
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.013
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.006
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	97896000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	84766000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	33512000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	862214000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	625114000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	358425000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	19700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14982000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	13981000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	86000000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	937069000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	724779000	usd
CY2022Q4	bgne	Deferred Tax Assets Property Lease Liability Obligation DeferredTaxAssetsPropertyLeaseLiabilityObligation	10348000	usd
CY2021Q4	bgne	Deferred Tax Assets Property Lease Liability Obligation DeferredTaxAssetsPropertyLeaseLiabilityObligation	11571000	usd
CY2020Q4	bgne	Deferred Tax Assets Property Lease Liability Obligation DeferredTaxAssetsPropertyLeaseLiabilityObligation	9066000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	63156000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3644981000	usd
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	bgne	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	10098000	usd
CY2021Q4	bgne	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	11322000	usd
CY2020Q4	bgne	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	8843000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1927779000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1744240000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1189755000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1943775000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1758409000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1200547000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	15996000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	14169000	usd
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	10792000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	229550000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	254768000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5077247000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9925000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7123000	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4633000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1630000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2802000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2497000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	7000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11555000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9925000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7123000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2022Q4	bgne	Tax Benefit From Foreign Tax Status TaxBenefitFromForeignTaxStatus	3894000	usd
CY2022Q4	bgne	Tax Benefit From Foreign Tax Status Per Share TaxBenefitFromForeignTaxStatusPerShare	0.01
CY2022Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	2379000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	415000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	112000	usd
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-219000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	309000	usd
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	109000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1000	usd
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022	bgne	Accounts Receivable Allowance For Credit Loss Exchange Rate Changes AccountsReceivableAllowanceForCreditLossExchangeRateChanges	14000	usd
CY2021	bgne	Accounts Receivable Allowance For Credit Loss Exchange Rate Changes AccountsReceivableAllowanceForCreditLossExchangeRateChanges	-6000	usd
CY2020	bgne	Accounts Receivable Allowance For Credit Loss Exchange Rate Changes AccountsReceivableAllowanceForCreditLossExchangeRateChanges	3000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	211000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	415000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	112000	usd
CY2022Q4	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	71488000	usd
CY2021Q4	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	87239000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	20478000	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	58579000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	22777000	usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	12010000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	3039000	usd
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	5052000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3664000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1695000	usd
CY2022Q4	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	58950000	usd
CY2021Q4	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	78538000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1510000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2982000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34647000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	24078000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216553000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	270173000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	109000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	109000	usd
CY2022Q4	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	22025000	usd
CY2021Q4	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	14140000	usd
CY2022Q4	bgne	Prepaid Supply Cost PrepaidSupplyCost	48642000	usd
CY2021Q4	bgne	Prepaid Supply Cost PrepaidSupplyCost	24237000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	804000	usd
CY2021Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	17162000	usd
CY2022Q4	bgne	Rental Deposits And Other RentalDepositsAndOther	7054000	usd
CY2021Q4	bgne	Rental Deposits And Other RentalDepositsAndOther	6609000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	91779000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	100792000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	170413000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	163049000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	184775000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	139966000	usd
CY2022Q4	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	139168000	usd
CY2021Q4	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	213922000	usd
CY2022Q4	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	51806000	usd
CY2021Q4	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	71560000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	18815000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	45661000	usd
CY2022Q4	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	41817000	usd
CY2021Q4	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	59639000	usd
CY2022Q4	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	30971000	usd
CY2021Q4	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	27307000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	467352000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	558055000	usd
CY2022Q4	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	38176000	usd
CY2021Q4	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	46352000	usd
CY2022Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	7760000	usd
CY2021Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	7814000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	159000	usd
CY2021Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	68000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46095000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	54234000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	328969000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	538117000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2268905000	cny
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	427565000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2724732000	cny
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	209148000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1442500000	cny
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	202113000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1288000000	cny
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	328969000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	29412000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	35136000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	44697000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	44697000	usd
CY2022Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	55206000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	21699000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	29263000	usd
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	18309000	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	2594000	usd
CY2021	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1054000	usd
CY2020	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	338000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2003815000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-1628591000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3617000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2003815000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1457816000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1624974000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1340729572	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340729572	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1206210049	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1206210049	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1085131783	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1085131783	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.50
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.50
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	108417254	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.96
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8999536	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.54
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.15
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	29707587	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.82
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	416509000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2717488	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.22
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	84991715	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.27
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6244524	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.46
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.40
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	17233853	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	367110000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1797498	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.27
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	72204888	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.08
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12516816	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.34
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.40
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5898217	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	52258000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2296634	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.46
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	76526853	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.85
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	745340712000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	58017219	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.67
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	673364735000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	73842956	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.60
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	734904195000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	62548000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	53571000	usd
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	55127000	usd
CY2021	bgne	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Exercise Multiple Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum	2.8
CY2020	bgne	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Exercise Multiple Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum	2.8
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	303162000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	240712000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	183481000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	9519000	usd
CY2021	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-1489000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-96178000	usd
CY2022	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-811000	usd
CY2022Q4	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2022Q4	bgne	Restricted Net Assets Required Statutory Reserve As Percentage Of Registered Capital RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital	0.50
CY2021Q4	bgne	Restricted Net Assets Appropriated To Statutory Reserves RestrictedNetAssetsAppropriatedToStatutoryReserves	0	usd
CY2020Q4	bgne	Restricted Net Assets Appropriated To Statutory Reserves RestrictedNetAssetsAppropriatedToStatutoryReserves	0	usd
CY2022Q4	bgne	Restricted Net Assets Appropriated To Statutory Reserves RestrictedNetAssetsAppropriatedToStatutoryReserves	0	usd
CY2022Q4	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2022	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	117293000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1415921000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1176283000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	308874000	usd

Files In Submission

Name	View Source	Status
0001651308-23-000036-index-headers.html	Edgar Link	pending
0001651308-23-000036-index.html	Edgar Link	pending
0001651308-23-000036.txt	Edgar Link	pending
0001651308-23-000036-xbrl.zip	Edgar Link	pending
bgne-20221231.htm	Edgar Link	pending
bgne-20221231.xsd	Edgar Link	pending
bgne-20221231_g1.jpg	Edgar Link	pending
bgne-20221231_g10.jpg	Edgar Link	pending
bgne-20221231_g11.jpg	Edgar Link	pending
bgne-20221231_g12.jpg	Edgar Link	pending
bgne-20221231_cal.xml	Edgar Link	unprocessable
bgne-20221231_def.xml	Edgar Link	unprocessable
bgne-20221231_pre.xml	Edgar Link	unprocessable
bgne-20221231_lab.xml	Edgar Link	unprocessable
bgne-20221231_g13.jpg	Edgar Link	pending
bgne-20221231_g14.jpg	Edgar Link	pending
bgne-20221231_g15.jpg	Edgar Link	pending
bgne-20221231_g16.jpg	Edgar Link	pending
bgne-20221231_g17.jpg	Edgar Link	pending
bgne-20221231_g18.jpg	Edgar Link	pending
bgne-20221231_g19.jpg	Edgar Link	pending
bgne-20221231_g2.jpg	Edgar Link	pending
bgne-20221231_g20.jpg	Edgar Link	pending
bgne-20221231_g21.jpg	Edgar Link	pending
bgne-20221231_g22.jpg	Edgar Link	pending
bgne-20221231_g23.jpg	Edgar Link	pending
bgne-20221231_g24.jpg	Edgar Link	pending
bgne-20221231_g25.jpg	Edgar Link	pending
bgne-20221231_g3.jpg	Edgar Link	pending
bgne-20221231_g4.jpg	Edgar Link	pending
bgne-20221231_g5.jpg	Edgar Link	pending
bgne-20221231_g6.jpg	Edgar Link	pending
bgne-20221231_g7.jpg	Edgar Link	pending
bgne-20221231_g8.jpg	Edgar Link	pending
bgne-20221231_g9.jpg	Edgar Link	pending
exhibit1044-amendmentno3to.htm	Edgar Link	pending
exhibit211-2022q4.htm	Edgar Link	pending
exhibit231-2022q4.htm	Edgar Link	pending
exhibit232-2022q4.htm	Edgar Link	pending
exhibit311-2022q4.htm	Edgar Link	pending
exhibit312-2022q4.htm	Edgar Link	pending
exhibit321-2022q4.htm	Edgar Link	pending
exhibit46-descriptionofsec.htm	Edgar Link	pending
exhibit991-disclosureforei.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
bgne-20221231_htm.xml	Edgar Link	completed
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONC
BeiGene, Ltd. Stock $onc

2023 Q1 Form 10-K Financial Statement

#000165130823000036 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC BeiGene, Ltd. Stock $onc

2023 Q1 Form 10-K Financial Statement

#000165130823000036 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC
BeiGene, Ltd. Stock $onc